Pharma Industrial India - Professional magazine for pharma industry suppliers and lab technology

NEWS ABOUT >

Biotechnology

Clean Rooms

Clinical Trials

Consultants

Digitalization

Drug Discovery & Development

Engineering

Global Pharma

Industrial talks

Ingredients

Lab Equipment

Logistics & Distribution

Manufacturing

Market

Outsourcing

Packaging

Quality / GMP

Regulation

Safety

Last edition

All magazines
Subscribe to our magazine

News about "ILUMYA"

Sun Pharma Announces US FDA Acceptance of sBLA Application for ILUMYA to Treat Adults with Active Psoriatic Arthritis

The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.

ILUMYA | 17/03/2026 | By News Bureau

Sun Pharma's Phase 3 Clinical Trials of ILUMYA in Active Psoriatic Arthritis Achieve Primary Endpoint

Sun Pharmaceutical Industries has reported positive top-line results from two Phase 3 trials (INSPIRE-1 and INSPIRE-2), demonstrating that ILUMYA (tildrakizumab 100 mg) significantly improved symptoms of active psoriatic arthritis over 24 weeks compared to placebo.

ILUMYA | 21/07/2025 | By Mrinmoy Dey | 299

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members